Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neovasc Inc (TSX: NVCN )

39.67 -0.67 (-1.66%)
Streaming Delayed Price Updated: 2:00 PM EDT, Mar 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 647
Open 40.31
Bid (Size) 36.50 (1)
Ask (Size) 41.70 (2)
Prev. Close 40.34
Today's Range 39.67 - 40.55
52wk Range 0.3650 - 41.20
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Neovasc Shareholders Approve Acquisition by Shockwave Medical
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Neovasc Announces German Reimbursement Renewal
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire

Performance

YTD
+96.39%
+96.39%
1 Month
+3.17%
+3.17%
3 Month
+160.13%
+160.13%
6 Month
+361.28%
+361.28%
1 Year
+7528.85%
+7528.85%

More News

Read More
Neovasc (NASDAQ: NVCN) (TSX: NVCN) Enters into Agreement to be Acquired by Shockwave Medical (NASDAQ: SWAV) for $100 Million & CVR
Via Spotlight Growth
Exposures Product Safety
Shockwave Medical Announces Agreement to Acquire Neovasc
From Shockwave Medical, Inc.
Via Globe NewsWire
Neovasc Announces Progress on COSIRA-II Clinical Trial
Via NewMediaWire
Neovasc Comments on European Heart Journal Publication
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property
Neovasc Announces Third Quarter Financial Results and Provides Corporate Update
Via NewMediaWire
Neovasc Reducer Obtains U.S. Outpatient Reimbursement
Via NewMediaWire
Neovasc to Report Third Quarter Financial Results on November 10, 2022
Via NewMediaWire
Neovasc Provides Corporate Update Following Clinical Data Release
Via NewMediaWire
Neovasc to Participate in LSI Europe 2022 Emerging MedTech Summit
Via NewMediaWire
Neovasc Comments on New ICD-10-CM Diagnosis Codes for Refractory Angina
Via NewMediaWire
Neovasc Announces Key Events at TCT 2022
Via NewMediaWire
Neovasc to Participate in H.C. Wainwright 24th Annual Global Investment Conference
Via NewMediaWire
Neovasc Announces Second Quarter Financial Results and Provides Corporate Update
Via NewMediaWire
Exposures Product Safety
Neovasc to Report Second Quarter Financial Results on August 11, 2022
Via NewMediaWire
Neovasc Announces FDA Approval of Planned COSIRA II Sub-studies and Single Arm Registry to Allow Inclusion of Additional Specified Patient Populations
Via NewMediaWire
Exposures Product Safety
Neovasc to Participate in Sidoti & Co. Summer Small Cap Virtual Investor Conference
Via NewMediaWire
Neovasc to Participate in H.C. Wainwright Global Investment Conference
Via NewMediaWire
Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule
Via NewMediaWire
Neovasc Announces First Quarter Financial Results and Provides Corporate Update
Via NewMediaWire
Neovasc to Report First Quarter Financial Results on May 12, 2022
Via NewMediaWire
Neovasc Comments on European Heart Journal Publication
Via NewMediaWire
Neovasc Announces Effective Date of Share Consolidation
Via NewMediaWire
Neovasc to Participate in Bloom Burton & Co. Healthcare Investment Conference
Via NewMediaWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.